SARS-CoV-2感染后隐球菌病的描述:真菌病研究组教育与研究联盟的疾病调查(MSG-19)
该研究通过真菌病研究组教育与研究联盟等渠道收集SARS-CoV-2感染后隐球菌病病例,共69例来自29个机构。隐球菌病诊断中位时间为SARS-CoV-2感染后22天。有随访者中,免疫功能正常组死亡率为72%(26/36),免疫功能受损组为48%(15/31),总体死亡率为59%。
要点
- SARS-CoV-2感染后隐球菌病诊断中位时间为22天(四分位距9-42天)。
- 有随访者中免疫功能正常组死亡率72%(26/36),免疫功能受损组48%(15/31)。
- 疾病表现(中枢神经系统感染、确诊/可能播散性疾病、呼吸道)与死亡率相关(P = .002)。
核心结论
- SARS-CoV-2感染后隐球菌病患者死亡率为59%,高于现代隐球菌队列。
- 免疫功能受损状态与隐球菌病表现及死亡率存在关联。
- 该系列强调当出现相关症状时,需对30天后的机会性感染进行临床和实验室评估。
研究设计与样本
- 通过真菌病研究组教育与研究联盟、美国疾病控制与预防中心新发传染病网络及传染病推特群组进行众包病例征集。
- 数据收集于基于网络的安全REDCap调查中,不含个人标识符。
- 共识别并提交来自29个独立机构场所的69例病例。
主要发现
- 隐球菌病诊断在SARS-CoV-2感染后中位22天(四分位距9-42天)。
- 有可用随访者中,免疫功能正常组死亡率为72%(26/36),免疫功能受损组为48%(15/31)(似然比4.01;P = .045)。
- 观察到疾病表现(中枢神经系统感染、确诊/可能播散性疾病及呼吸道)与死亡率相关(P = .002)。
- SARS-CoV-2感染后隐球菌病患者死亡率为59%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive fungal infections have been described throughout the COVID-19 pandemic. Cryptococcal disease after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been reported in several isolated case reports and 1 larger case series. We sought to describe cryptococcal infections following SARS-CoV-2 through establishing a database to investigate underlying risk factors, disease manifestations, and outcomes. METHODS: We created a crowdsourced call for cases solicited through the Mycoses Study Group Education and Research Consortium, the Centers for Disease Control and Prevention Emerging Infectious Diseases Network, and infectious diseases Twitter groups. Data were collected in a web-based and secure REDCap survey without personal identifiers. RESULTS: Sixty-nine cases were identified and submitted by 29 separate institutional sites. Cryptococcosis was diagnosed a median of 22 days (interquartile range, 9-42 days) after SARS-CoV-2 infection. Mortality among those with available follow-up was 72% (26/36) for the immunocompetent group and 48% (15/31) for the immunocompromised group (likelihood ratio, 4.01; P = .045). We observed a correlation between disease manifestation (central nervous system infection, proven/probable disseminated disease, and respiratory) and mortality (P = .002). CONCLUSIONS: The mortality rate of 59% for patients with cryptococcosis following SARS-CoV-2 is higher than that of modern Cryptococcus cohorts. There was an association between immunocompromised status and cryptococcal disease manifestations as well as mortality. Moreover, our series emphasizes the need for clinical and laboratory assessment of opportunistic infections beyond 30 days when concerning symptoms develop.
引用
- Walker J, McCarty T, McGwin G, et al. Description of Cryptococcosis Following SARS-CoV-2 Infection: A Disease Survey Through the Mycosis Study Group Education and Research Consortium (MSG-19). Clin Infect Dis. 2024. PMID: 37713207. doi:10.1093/cid/ciad551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。